Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

University College London
Sponsor

University College London

United Kingdom 250 Euston Road, NW1 2PG, United Kingdom

About the sponsor

The sponsor is deeply engaged in the field of oncology, with a particular focus on Hodgkin lymphoma. Their research efforts are directed towards improving treatment outcomes for patients with early-stage disease through innovative trial designs.

  • Hodgkin Lymphoma
  • Progression Free Survival
  • PET-response Adapted Design

By exploring new therapeutic combinations and response-adapted strategies, the sponsor aims to enhance the efficacy of existing treatments and contribute to the advancement of personalized cancer therapy.

About Specializations

University College London runs clinical trials in conditions such as Hormone-dependent prostate cancer, Hodgkin's disease, Renal cell carcinoma, Hypoxic-ischaemic encephalopathy, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Hormone-dependent prostate cancer

Recruiting

A study to evaluate the effects of lutetium (177lu) vipivotide tetraxetan in patients with metastatic hormone sensitive prostate cancer receiving androgen deprivation therapy.

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Lutetium (177LU) vipivotide tetraxetan
  • Sponsor:University College London

Hodgkin's disease

Recruiting

Phase III Trial Comparing ABVD vs A2VD Treatment With PET-Guided Radiation Therapy for Patients With Early Stage Hodgkin Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin
  • Sponsor:University College London

Renal cell carcinoma

Recruiting

Study on Durvalumab and Tremelimumab for Patients with Kidney Cancer at Risk of Recurrence After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:University College London

Hypoxic-ischaemic encephalopathy

Not yet recruiting

Study of intravenous melatonin safety and dosing in newborns with moderate to severe hypoxic-ischaemic encephalopathy receiving therapeutic hypothermia treatment

InvestigationalNo placebo
Countries:IrelandIreland
  • Participants:0–17 years
  • Substances:Melatonin
  • Sponsor:University College London

Gastric cancer+5

Not recruiting

Study on Aspirin's Effect on Recurrence and Survival in Patients with Non-Metastatic Breast, Colon, Rectal, Stomach, Esophageal, and Prostate Cancer

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University College London

Growth hormone deficiency

Not recruiting

Study on Growth Hormone Deficiency: Comparing Effects of Continuing vs. Stopping Somatropin Treatment in Pubertal Children with Isolated Growth Hormone Deficiency

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Somatropin
  • Sponsor:University College London

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.